Scarlett Spring currently serves as Co-Founder and Chief Executive Officer of TapRoot Interventions & Solutions, a platform technology company focused on providing real-time, tailored interventions to caregivers managing patients with Alzheimer’s and dementia behaviors. She previously served as President and Chief Commercial Officer for VisionGate, Inc., a clinical-stage pharmaceutical and diagnostics company developing products for the early detection, prevention, and treatment of lung cancer. Prior to VisionGate, Ms. Spring served in various sales and commercial roles of increasing responsibility at Merck and AstraZeneca Pharmaceuticals. At AstraZeneca, she was involved in the successful launches of Prilosec®, Nexium®, Crestor® and Iressa®, and managed the hormonal portfolio for AstraZeneca Oncology. Ms. Spring also previously served as Executive Vice President and Chief Operating Officer of the Greater Phoenix Economic Council. She currently serves on the Arizona Bioscience Board and Risk Capital Committee of the Flinn Foundation, as well as on the Boards of Republic Bank of Arizona and the Arizona Sports and Tourism Authority. She received a Bachelor’s degree in Marketing from the University of Texas at Austin and a Master’s in Business Administration from Pepperdine University.
Mr. Mayes is the Chief Executive Officer and a board member of Antios Therapeutics. Prior to Antios and drawing on inspiration from his son’s epilepsy diagnosis, he raised $40 million from prominent investors and founded the clinical-stage pharmaceutical company, Engage Therapeutics, to develop a product candidate for seizures. Upon approval, Staccato® Alprazolam will be the first and only drug-device-combination for the rapid termination of an active epileptic seizure. Engage was sold to UCB in 2020 in a deal valued at $270 million following the successful completion of its randomized, phase 2b clinical study. Prior to Engage, Mr. Mayes played an integral role in the growth of Advaxis Immunotherapies (NASDAQ: ADXS), a biotech company developing immuno-oncology therapies for patients with hard-to-treat cancers through its bacterial vector system, Lm Technology™. As its Chief Operating Officer, he was instrumental in helping to secure in excess of $200 million in follow-on funding and developing partnerships with companies such as Amgen, AstraZeneca and Merck & Co. From 2004 to 2010, Mr. Mayes served as Vice President, General Counsel, and Chief Compliance Officer at ImClone Systems Corporation. During his tenure at ImClone, Mr. Mayes supported the clinical development and commercialization of ERBITUX® and contributed significantly to activities that resulted in its acquisition by Eli Lilly for $6.5 billion in 2008. Mr. Mayes is a cum laude graduate of Syracuse University where he was recognized as a Remembrance Scholar and he earned his J.D. degree magna cum laude from the Temple University School of Law where he was the Articles Editor on the Temple Law Review.
Anthony B. Evnin, Ph.D. has been a Partner at Venrock, a venture capital firm, since 1975. Dr. Evnin currently serves on the Board of Directors of AVEO Pharmaceuticals and Infinity Pharmaceuticals as well as on the Boards of two private companies, Constellation Pharmaceuticals and Juno Therapeutics. He is a Trustee of The Rockefeller University, a Member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center, a Trustee of The Jackson Laboratory, a Director of the New York Genome Center, a Member of the Board of Directors of the Albert and Mary Lasker Foundation, and a Trustee Emeritus of Princeton University. Dr. Evnin received an A.B. in chemistry from Princeton University and a Ph.D. in chemistry from the Massachusetts Institute of Technology.
Dr. Epperly brings over 15 years of deep oncology experience as a physician and scientist blending medicine and business with a proven track record in oncology drug development and launches. She has served as Senior Vice President of Strategy and Operations at Iovance Biotherapeutics, a public clinical-stage immuno-oncology company, leading clinical operations overseeing all clinical trials, developing and implementing business strategy to advance drug development including clinical trial design, global business development, and the commercial operating model for the launch of Tumor Infiltrating Lymphocytes (TIL), with the potential to be the first approved cell therapy for solid tumor cancers. Previously she served as the US Chief Operating Officer at VBL Therapeutics, a public biopharmaceutical focused on first-in-class cancer treatments, where she helped lead corporate strategy, financing, business development, designed a US commercial operating model and marketing plan, and supported immuno-oncology clinical drug development. Prior to VBL, in her 7 years at Bristol Myers Squibb she delivered results across multiple leadership roles spanning marketing, including helping drive the launches of OPDIVO® (nivolumab) and YERVOY® (ipilimumab) in 6+ tumor indications under accelerated timelines, M&A leading global transactions and negotiations, strategic operations and medical strategy in the US Immuno-Oncology Business. Previously at Goldman Sachs International in London she served as an equity analyst in Global Pharmaceutical and Biotechnology Investment Research. She holds a Bachelor’s degree in Biochemistry and Biology from the University of Virginia, a Doctorate of Medicine and a Masters of Public Health from the University of North Carolina at Chapel Hill (UNC). She completed her medical training at the UNC Hospitals. She trained at the National Cancer Institute of the NIH in translational medicine, experimental cancer immunology in checkpoint inhibition, tumor suppressor genes, and bone marrow transplant clinical trials.
Dr. Cullen received his medical degree from Harvard Medical School. He conducted his residency in internal medicine at Beth Israel Hospital in Boston, MA, and fellowship in oncology with the National Cancer Institute, National Institutes of Health in Bethesda, MD. Prior to joining the University of Maryland School of Medicine, Dr. Cullen served as Professor of Medicine, Oncology and Otolaryngology, at Georgetown University, and Interim Director of the Lombardi Cancer Center at Georgetown University. He received his Bachelor of Arts degree from Dartmouth College.
At the University of Maryland Greenebaum Comprehensive Cancer Center, which is ranked as one of the nation’s top cancer programs, Dr. Cullen oversees a staff of 275 physicians and researchers. Under his leadership, the cancer center has expanded its clinical and research programs significantly and was named a National Cancer Institute-designated cancer center in 2008 and a comprehensive cancer center in 2016. Dr. Cullen’s laboratory examines the mechanisms of chemotherapy resistance in head and neck cancer. His team was the first to describe racial survival disparities in head and neck cancer. In 2011, he was appointed by President Obama to a five-year term as a member of the National Cancer Advisory Board, an advisory committee to the National Cancer Institute. He has served as chairman of the Board of the American Cancer Society and is a recipient of the American Cancer Society Excellence in Research Award.
Michael P. Bailey serves as president and chief executive officer of AVEO and a member of the company’s board of directors, bringing more than 25 years of experience in the pharmaceutical industry to the company. He joined AVEO in 2010 as the company’s chief commercial officer, was named chief business officer in 2013 and assumed his current roles in January 2015. He currently serves on the board of directors of IMV Inc., a clinical-stage biopharmaceutical company developing a new class of cancer immunotherapies and vaccines to treat infectious diseases such as COVID-19. Mr. Bailey joined AVEO from Synta Pharmaceuticals, where he served as senior vice president, business development, and chief commercial officer since 2008. Prior to joining Synta, Mr. Bailey led ImClone Systems’ (now Eli Lilly) Worldwide Commercial Organization. During his nine-year tenure at ImClone, he was responsible for commercial aspects of the planning and launch of ERBITUX® (cetuximab) across multiple oncology indications, as well as new product planning for the ImClone development portfolio, which included CYRAMZA® (ramucirumab) and necitumumab. In addition, Mr. Bailey was a key member of the strategic leadership committees for ImClone and its North American and worldwide partnerships. Prior to joining ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc., and was a key member of their global commercial partnership teams. Mr. Bailey started his career in the pharmaceutical industry as part of SmithKline Beecham’s Executive Marketing Development Program, where he held a variety of commercial roles, including sales, strategic planning, and product management. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from the Mendoza College of Business at University of Notre Dame.
Kenneth M. Bate has served as a director since December 2007. He is currently an independent biotech industry consultant. Mr. Bate previously served as President and Chief Executive Officer of Archemix, Inc. from May 2009 to January 2012. From 2006 to 2009, Mr. Bate served in various positions at Nitromed, Inc., most recently as President and Chief Executive Officer. From 2002 to 2005, Mr. Bate served as Chief Financial Officer and head of commercial operations of Millennium Pharmaceuticals Inc. Mr. Bate served as the Chairman of the Board of Cubist Pharmaceuticals, Inc. from 2011 to 2015. In addition to serving on the Board of Directors of AVEO, Mr. Bate serves on the Board of Genocea Biosciences, Inc., Catabasis Pharmaceuticals, Inc. Epizyme, Inc. and TransMedics, Inc. Mr. Bate received his B.A. in Chemistry from Williams College and his M.B.A. from the Wharton School of the University of Pennsylvania.